Zobrazeno 1 - 10
of 327
pro vyhledávání: '"Alexander T, Cohen"'
Autor:
Daniël Duijzer, Maria A. de Winter, Marc Carrier, Alexander T. Cohen, John-Bjarne Hansen, Karin A.H. Kaasjager, Ajay K. Kakkar, Saskia Middeldorp, Henrik T. Sørensen, Frank L.J. Visseren, Philip S. Wells, Jannick A.N. Dorresteijn, Mathilde Nijkeuter
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 8, Iss 7, Pp 102569- (2024)
Background: After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE
Externí odkaz:
https://doaj.org/article/762594d3a38a49cfa6a9cbbcee03a280
Autor:
Kevin G. Pollock, Carissa Dickerson, Manjit Kainth, Sarah Lawton, Michael Hurst, Daniel M. Sugrue, Chris Arden, D. Wyn Davies, Anne-Céline Martin, Belinda Sandler, Jason Gordon, Usman Farooqui, David Clifton, Christian Mallen, Jennifer Rogers, Nathan R. Hill, A. John Camm, Alexander T. Cohen
Publikováno v:
BMC Primary Care, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Conducting effective and translational research can be challenging and few trials undertake formal reflection exercises and disseminate learnings from them. Following completion of our multicentre randomised controlled trial, whic
Externí odkaz:
https://doaj.org/article/27c52a2dc0a040fbb3abfb3cdcb472c8
Autor:
Gregory J. Fermann, Brooks D. Cash, Nayantara Coelho‐Prabhu, Marc Maegele, Roland Bingisser, Vinay Sehgal, Alexander T. Cohen, Anna Hundt Golden, Jon Russo, Mark Price, Allen Mangel, Bruce Koch, Mary J. Christoph, Truman J. Milling Jr.
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 4, Iss 5, Pp n/a-n/a (2023)
Abstract Objective To define and contextualize life‐threatening gastrointestinal (GI) bleeding in the setting of factor Xa (FXa) inhibitor therapy and to derive a consensus‐based, clinically oriented approach to the administration of FXa inhibito
Externí odkaz:
https://doaj.org/article/1270a691872e4c78bfdff0c178ab6aa6
Autor:
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Publikováno v:
Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-12 (2022)
Abstract Cancer-associated thrombosis (CAT) poses a significant disease burden and the incidence in Asian populations is increasing. Anticoagulation is the cornerstone of treatment, but can be challenging due to the high bleeding risk in some cancers
Externí odkaz:
https://doaj.org/article/f8e8245f9f74492e9c9da1eac8ac3864
Autor:
Kimberly Snow Caroti PharmD, Alok A. Khorana MD, Cecilia Becattini MD, Agnes Y.Y. Lee MD, Anders Ekbom MD, Marc Carrier MD, Alexander T. Cohen MD, Christopher Brescia BS, Khaled Abdelgawwad MSc, MBA, George Psaroudakis PhD, Marcela Rivera PhD, Bernhard Schaefer BS, Gunnar Brobert PhD, Craig I. Coleman PharmD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Cancer-associated venous thromboembolism (CAT) guidelines recommend direct oral anticoagulants as alternatives to low-molecular-weight heparin (LMWH) in most patients. This study compared the effectiveness and safety of rivaroxaban versus LMWH for a
Externí odkaz:
https://doaj.org/article/d9a5ff0f4ce140bdb2925b75475697e0
Autor:
Craig I. Coleman, Mauricio Concha, Bruce Koch, Belinda Lovelace, Mary J. Christoph, Alexander T. Cohen
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
ObjectiveTo develop a composite score for predicting functional outcome post–intracerebral hemorrhage (ICeH) using proxy measures that can be assessed retrospectively.MethodsData from the observational ERICH study were used to derive a composite sc
Externí odkaz:
https://doaj.org/article/1dd38eaaabda47d78aa531dabd2e752b
Autor:
Ioannis T. Farmakis, Stefano Barco, Anna C. Mavromanoli, Giancarlo Agnelli, Alexander T. Cohen, George Giannakoulas, Charles E. Mahan, Stavros V. Konstantinides, Luca Valerio
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 20 (2022)
Background As mortality from pulmonary embolism (PE) decreases, the personal and societal costs among survivors are receiving increasing attention. Detailing this burden would support an efficient public health resource allocation. We aimed to provid
Externí odkaz:
https://doaj.org/article/2bb0d176ed62401394dd1e60480240ed
Autor:
Alexander T. Cohen, Megan Lewis, Augusta Connor, Stuart J. Connolly, Patrick Yue, John Curnutte, Raza Alikhan, Peter MacCallum, Joachim Tan, Laura Green
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 3, Iss 2, Pp n/a-n/a (2022)
Abstract Objective Compare 30‐day mortality among patients receiving the specific reversal agent andexanet alfa versus replacement prothrombin complex concentrate (PCC) in the management of direct‐acting oral anticoagulant (DOAC)–related bleeds
Externí odkaz:
https://doaj.org/article/9a49da103d534d07a8f7b929a8e370b3
Autor:
Rodrigo Abensur Athanazio MD, PhD, José Manuel Ceresetto MD, Luis Javier Marfil Rivera MD, Gabriela Cesarman-Maus MD, PhD, Kenny Galvez MD, Marcos Arêas Marques MD, Aldo Hugo Tabares MD, Carlos Alberto Ortiz Santacruz MD, Fernando Costa Santini MD, Luis Corrales MD, Alexander T. Cohen MBBS, MSc, MD, FRACP, FESC
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associat
Externí odkaz:
https://doaj.org/article/8ab748bf4e814de590a626a9dc9e0e02
Autor:
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt, Patrick Hlavacek, Birol Emir, Allison Keshishian, Huseyin Yuce, Xuemei Luo
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0274969 (2022)
This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, o
Externí odkaz:
https://doaj.org/article/68fee702215d44e0afbb4580c3e8f127